Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 3:36 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1153–1176 of 1,429 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: opiates Clear all

Conditions: Opioid-Related Disorders
Interventions: Buprenorphine/naloxone; Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 21 Years to 50 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2000
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Opiates, Healthy
Interventions: Vicks VapoInhaler, Poppy seeds; Drug · Other
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Malignant Neoplasms of Female Genital Organs, Gynecologic Cancer
Interventions: Bupivacaine, Liposomal Bupivacaine, Oxycodone, Pill Diary, Symptom Questionnaire; Drug · Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Opioid Tolerance
Interventions: Low Dose Naloxone; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 1 Day to 18 Years
Enrollment: 128 participants
Timeline: 2002 – 2004
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Schizophrenia, Mental Disorders, Alcohol Abuse, Alcoholism, Alcohol-related Disorders
Interventions: Naltrexone or Placebo; Drug
Lead sponsor: State University of New York - Upstate Medical University; Other
Eligibility: 18 Years to 69 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 4
States / cities: Syracuse, New York

Conditions: Osteoarthritis
Interventions: Buprenorphine, oxycodone immediate-release; Drug
Lead sponsor: Purdue Pharma LP; Industry
Eligibility: 40 Years and older
Enrollment: 418 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 23
States / cities: Birmingham, Alabama • Chula Vista, California • Roseville, California + 18 more

Conditions: Tonsillitis, Pain
Interventions: Codeine with acetaminophen, Tramadol suspension; Drug
Lead sponsor: Children's Hospitals and Clinics of Minnesota; Other
Eligibility: 4 Years to 15 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Knee Arthroplasty, Total
Interventions: Liposomal Bupivacaine, Bupivacaine, Clonidine, Epinephrine, Buprenorphine and Dexamethasone (BPV-CEBD) Combination; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Pain
Interventions: Intrathecal morphine injection, EXPAREL; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 5
States / cities: Port Saint Lucie, Florida • Minneapolis, Minnesota • New Brunswick, New Jersey + 2 more

Conditions: Healthy
Interventions: buprenorphine; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 50 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Opioid-Related Disorders, Drug Addiction, Pregnancy Related, Substance Abuse, Drug Abuse, Neonatal Abstinence Syndrome, Neonatal Opioid Withdrawal Syndrome, Drug Abuse in Pregnancy
Interventions: Buprenorphine Injection, Buprenorphine Sublingual Product; Drug
Lead sponsor: T. John Winhusen, PhD; Other
Eligibility: 18 Years to 41 Years · Female only
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 12
States / cities: Jacksonville, Florida • Boston, Massachusetts • Albuquerque, New Mexico + 8 more

Conditions: Opioid Use Disorder, Opioid Dependence
Interventions: Naltrexone; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 16 Years to 25 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 2
States / cities: New York, New York

Conditions: Opiate Dependence
Interventions: Medisorb naltrexone 380 mg; Drug
Lead sponsor: Alkermes, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 11
States / cities: Colton, California • Oceanside, California • Lauderhill, Florida + 7 more

Conditions: Overdose
Interventions: Brief youth overdose prevention education, Information about Naloxone, Usual standard of care; Behavioral · Other
Lead sponsor: Boston Medical Center; Other
Eligibility: 13 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Opiate-Related Disorders, Cocaine-Related Disorders
Interventions: Methadone, Contingency Management, Methadone dose, Contingency Management/Noncontingent Incentives; Drug · Behavioral
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Psychology, Social
Interventions: Naltrexone; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 35 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Opioid Overdose, Opiate Overdose
Interventions: Nalmefene Injection, Naloxone Injection; Drug
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Opioid Overdose
Interventions: Buprenorphine/Naloxone; Drug
Lead sponsor: Nassima Ait-Daoud Tiouririne; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Healthy
Interventions: Buprenorphine HCl/Naloxone HCl; Drug
Lead sponsor: NanoSHIFT LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Pain, Virtual Reality, Placebo, Temporomandibular Disorder
Interventions: Active Virtual Reality, sham Virtual Reality, No Intervention, Naloxone, Saline, Natural history; Behavioral · Other · Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 88 Years
Enrollment: 259 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HIV, AIDS, Opioid Dependence, Drug Dependence
Interventions: Extended-Release Naltrexone; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 151 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2016
U.S. locations: 3
States / cities: Hartford, Connecticut • New Haven, Connecticut • Springfield, Massachusetts

Conditions: Methamphetamine Dependence
Interventions: Naltrexone plus N-Acetyl Cysteine, Placebo; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 65 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Infection, Human Immunodeficiency Virus
Interventions: BMS-663068, Methadone, Buprenorphine and Norbuprenorphine; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 2
States / cities: Orlando, Florida • Overland Park, Kansas

Conditions: Alcoholism, Depression
Interventions: naltrexone (Revia), sertraline (Zoloft), Placebo; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 21 Years to 65 Years
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2006
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

Buprenorphine/Naloxone for Treatment of Opiate Dependence - 9

Factors Affecting Methamphetamine and Opiates Drug Testing

Wound Infiltration With Liposomal Bupivacaine vs. Standard Wound Infiltration With Bupivacaine in Patient's Undergoing Open Gynecologic Surgery on an Enhanced Recovery Pathway

Impact of Low Dose Naloxone on Fentanyl Requirements in Pediatric ICU Patients

Naltrexone Treatment of Alcohol Abuse in Schizophrenia

Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Osteoarthritis Pain

A Comparison of Postoperative Tramadol Versus Acetaminophen With Codeine in Children Undergoing Tonsillectomy

Liposomal Bupivacaine vs Perineural Adjuvants in Adductor Canalf and iPACK Blocks in Total Knee Arthroplasty

Evaluation of the Safety and Efficacy of EXPAREL When Administered Into the TAP in Subjects Undergoing Cesarean Section

Buprenorphine Disposition and Cyclosporine

Medication Treatment for Opioid Use Disorder in Expectant Mothers

Medication-Assisted Treatment for Youth With Substance Use Disorders

ALK21-021: A Safety Study of Medisorb® Naltrexone (VIVITROL®) Administered to Health Care Professionals

A Universal Primary Care Based Intervention to Reduce Youth Overdose Risk

Treatment of Heroin and Cocaine With Methadone Maintenance and Contingency Management

Neuropharmacological Basis of Social Connection: The Role of Opioids

Nalmefene vs Naloxone for the Treatment of Recurrent Respiratory Depression After Opioid Overdose

Measures to Improve Outcomes After an Opioid Overdose

Study to Assess the PK Profile of NanoBUP Capsules Relative to Suboxone

Neural Mechanisms of Immersive Virtual Reality in Chronic Pain

Naltrexone for Opioid Dependent Released Human Immunodeficiency Virus Positive (HIV+) Criminal Justice Populations

N-Acetyl Cysteine Plus Naltrexone in Methamphetamine Dependence

A Study to Assess the Drug-drug Interaction of BMS 663068 With Methadone and Also With Buprenorphine/Naloxone

Sertraline for Alcohol Dependence and Depression